Pioneering diagnostics
E.g., 10/12/2018
E.g., 10/12/2018
PreviousNext

bioMérieux receives FDA clearance for expanded pathogen identification capability on VITEK® MS

31 July, 2017

bioMérieux, a world leader in the field of in vitro diagnostics, today announced that VITEK® MS, its MALDI-TOF1 Mass...

Sysmex and bioMérieux Agreed to Dissolve the Joint Venture Sysmex bioMérieux Co., Ltd.

27 July, 2017

Sysmex Corporation (“Sysmex”) and bioMérieux S.A. (“bioMérieux”) (Paris:BIM) announce they have agreed to transfer all of Sysmex’ holdings in Sysmex bioMérieux Co., Ltd. (Tokyo, Japan) to bioMérieux thereby dissolving the joint venture created by and between the...

Second-Quarter 2017 Business Review

20 July, 2017

  • Good sales dynamic confirmed in second-quarter 2017, with sales up 11.3% over the first half at constant exchange rates and scope of consolidation:
    • €1,134 million in sales
    • Up 13.3% as reported
  • Noticeable...

boMérieux receives FDA Clearance for BioFire's FilmArray® Respiratory Panel 2 (RP2)

The FilmArray® RP2 reduces sample-to-result time to only 45 minutes while enhancing pathogen coverage and overall sensitivity

01 June, 2017

 

bioMérieux, a world leader in the field of in vitro diagnostics, today announced that BioFire Diagnostics, its molecular biology affiliate, has received 510(k) clearance from the FDA for the FilmArray® Respiratory Panel 2 (RP2). The FilmArray®...

bioMérieux – First-Quarter 2017 Business Review

20 April, 2017

  • Strong sales dynamic in first-quarter 2017, with sales up 13.7% at constant exchange rates and scope of consolidation:
    • €568 million in sales
    • Up 16.3% as reported...

The FilmArray® Respiratory Panel 2 plus (RP2plus) gets CE marked

20 April, 2017

bioMérieux, a world leader in the field of in vitro diagnostics, today announced that the FilmArray® Respiratory Panel 2...

bioMérieux receives FDA 510(k) clearance for its BacT/ALERT® VIRTUO™ fully automated blood culture system

05 April, 2017

bioMérieux, a major player in the field of in vitro diagnostics, and the world leader in microbiology, announces that BacT/ALERT® VIRTUO™, its fully automated blood culture system, has received 510(k) clearance from the U.S. Food and Drug...

bioMérieux – 2016 Financial Results

01 March, 2017

  • Remarkable growth in sales in 2016, up 9.6% at constant exchange rates and scope of consolidation:
    • €2,103 million in sales
    • Up 7.1% as reported...

bioMérieux’s VIDAS® B•R•A•H•M•S PCT™ becomes the first FDA-cleared procalcitonin assay as an aid for antibiotic stewardship in respiratory infections and sepsis

24 February, 2017

bioMérieux, a world leader in the field of in vitro diagnostics, has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the expanded use of VIDAS® B•R•A•H•M•S PCT™, an automated...

bioMérieux and Banyan Biomarkers Partner to Develop, Validate and Market Blood-Based Biomarkers for Traumatic Brain Injury

19 January, 2017

bioMérieux, a world leader in the field of in vitro diagnostics and Banyan Biomarkers, an innovative biomarkers company developing blood tests capable of diagnosing traumatic brain injuries (TBI), announced today that they have entered into a partnership. Under the terms of the...

PreviousNext